The Annual General Meeting of Lerøy Seafood Group ASA will be held on 27 May 2026 at 10:00 (CEST) as a digital meeting. The notice of the Annual General Meeting, including the agenda and related information on participation, advance voting and proxy, is enclosed. The notice and the associated attachments are also available on the Company’s website: https://www.leroyseafood.com/en/investor/corporate-governance/generalmeetings/ This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.AttachmentLSG-Notice-of-annual-general-meeting

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors. “We are pleased to nominate Lykke to our Board of Directors,” said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. “Her extensive experience in global drug development and broad perspective across therapeutic areas will complement the expertise of our Board. As we continue to advance our pipeline and strategy, her insights will be valuable in supporting ProQR’s...

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in adults determined to be at high risk for mpox infection. The expanded indication in Singapore is supported by existing human safety data and data from a well-controlled animal study in which ACAM2000® vaccine was shown to be effective in protecting against mpox virus exposure. This regulatory milestone expands the authorized use of ACAM2000® in Singapore to support public health preparedness and response efforts. “The Singapore HSA approval of ACAM2000® for immunization against mpox in high-risk individuals demonstrates the strength and breadth...

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. Participants may access the webcast by registering...

Introducing a New Way to Measure and Understand Online Reputation, Powered by ReputScore — Ealixir’s Proprietary AI-Driven Reputation Metric MIAMI, Fla., April 30, 2026 (GLOBE NEWSWIRE) — Ealixir Inc. (OTCID: EAXR) (“Ealixir” or the “Company”), a digital identity infrastructure company specializing in online reputation management, today announced the beta launch of RepuTrust, its AI-powered digital identity platform. Beginning today, select users will receive early access to the RepuTrust platform, powered by an AI-driven engine that searches, analyzes, and scores online content. RepuTrust builds on the development of ReputScore, originally introduced as a standalone application designed to analyze the global digital footprint of individuals and generate a score of 1 to 100. We have since evolved ReputScore into a proprietary...

SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target for the month of May. The Company will provide a further update when available. Transaction Details As previously disclosed in the Company’s news release dated November 19, 2025 (here), upon the...

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company’s website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921...

RENO, Nev., April 30, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, today announced that the Company will release its financial and operational results for the first quarter ended March 31, 2026 after market close on Thursday, May 14, 2026. The earnings press release will be followed by a conference call on Thursday, May 14, 2026, at 4:30 PM Eastern Time. Interested investors and other parties may access the live webcast via the link found here or through the Events and Presentations page within the Investor Relations section of Dragonfly Energy’s website at https://investors.dragonflyenergy.com/events-and-presentations/default.aspx. The conference call can also be accessed by dialing (833) 461-5787...

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance...